A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

Starting soon · Phase 3 · Has a placebo group

Conditions studied: Chronic Pruritus of Unknown Origin

In brief

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Key facts

Study ID

NCT07700056

Run by

Novartis Pharmaceuticals

People needed

180

Starts

2026-08-14

Expected to finish

2030-04-15

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.